Abstract: This disclosure relates to systems and methods that identify, predict, and rank immunogenic T-cell epitopes. In particular, this disclosure identifies epitopes that arose from disease-associated mutations, wherein the epitopes are predicted to elicit immune response from T cells. Specifically, this disclosure simultaneously considers peptide-level information, including MHC Class I and II presentation, helper and cytotoxic T cell response and sample-level information, including mutation clonality and MHC allele dosage. In some embodiment, the systems and methods are used for personalized treatment of cancers.

Abstract: Provided is a kit for detecting MET fusion, including MET gene fusion and MET exon 14 skipping. The kit includes a set of MET fusion-specific primer pairs and a set of MET fusion-specific probes. Also provided is a method for detecting MET fusion, including generating an amplified target cDNA to hybridize with the set of MET fusion-specific probes in a single reaction and detecting the probe-bound product to identify all possible MET fusions in a biological sample.

Abstract: This disclosure relates to systems and methods that identify, predict, and rank immunogenic T-cell epitopes. In particular, this disclosure identifies epitopes that arose from disease-associated mutations, wherein the epitopes are predicted to elicit immune response from T cells. Specifically, this disclosure simultaneously considers peptide-level information, including MHC Class I and II presentation, helper and cytotoxic T cell response and sample-level information, including mutation clonality and MHC allele dosage. In some embodiment, the systems and methods are used for personalized treatment of cancers.

Abstract: Disclosed herein is a method for determining the prognosis of a subject diagnosed with hepatocellular carcinoma based on the expression level of at least one microRNA in the non-cancerous liver tissue of the subject. According to various embodiments of the present disclosure, expression levels of miR-486-3p, miR-876-5p, and miR-381 are positively associated with a favorable prognosis, while expression levels of miR-30c, miR-432, and miR-15b are negatively associated with a favorable prognosis.

Abstract: The present invention discloses a method for simultaneously detecting multiple small nucleic acids, which comprises steps: mixing a specimen, fluorescent probes, and bridge nucleic acids having different lengths to form a tested liquid; hybridizing the mixed short nucleic acid molecules, probes and bridge nucleic acids; adding ligases to enable the ligations of the short nucleic acid molecules and the fluorescent probes with the bridge nucleic acids being the templates; injecting the tested liquid into a capillary, and applying a voltage to the capillary to generate an electrophoresis effect and separate the hybridization products; and using laser to induce different fluorescent rays from different reaction products, and measuring the fluorescent rays, whereby the present invention can simultaneously detect multiple types of short nucleic acid molecules in a single capillary.

Abstract: The present invention discloses a quantitative analysis method for microRNAs, wherein a fluorescence-labeled DNA probe, which is equinumerous and completely complementary to a microRNA, hybridize with the microRNA. The products of hybridization include the fluorescence-labeled DNA probe containing 22 nucleotides and the probe-microRNA duplex containing 22 base pairs. The products of hybridization is introduced into a capillary by the pressure difference between two ends of the capillary and the siphon effect and separated by electrophoresis. A laser is used to induce fluorescence from the products of hybridization. Then, the intensities of fluorescence are measured and analyzed.

Abstract: This invention relates to methods for treating retinopathy and repairing tissue damage. The methods include administering to a subject in need thereof an effective amount of one or more compounds of the following formula. Each variable in this formula is defined in the specification.

Abstract: This invention relates to a method for treating inflammatory diseases or immune diseases, developmental or degenerative diseases, or tissue injuries. The method includes administering to a subject in need thereof an effective amount of one or more compounds of the following formula. Each variable in this formula is defined in the specification.

Abstract: This invention relates to methods for treating retinopathy and repairing tissue damage. The methods include administering to a subject in need thereof an effective amount of one or more compounds of the following formula. Each variable in this formula is defined in the specification.

Abstract: This invention relates to a method for treating inflammatory diseases or immune diseases, developmental or degenerative diseases, or tissue injuries. The method includes administering to a subject in need thereof an effective amount of one or more compounds of the following formula. Each variable in this formula is defined in the specification.

Abstract: A method of determining whether a subject is suffering from or at risk for developing cancer. The method involves providing a sample from a subject, and determining the level of HM74, LGR6, GPR88, or GPR49 gene expression or protein activity in the sample. The level of HM74, LGR6, GPR88, or GPR49 gene expression or protein activity in the sample, if higher than that in a sample from a normal subject, indicates that the subject is suffering from or at risk for developing cancer. Also disclosed are a method of identifying a compound for treating cancer, a method of treating cancer, and a pharmaceutical composition or a packaged product for treating cancer.